Advertisement

Drug Delivery and Translational Research

, Volume 9, Issue 5, pp 1008–1016 | Cite as

Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep

  • Herman Weiss
  • Bridget Martell
  • Ginger D. Constantine
  • Sarah M. Davis
  • Justin D. Vidal
  • Philip R. Mayer
  • Martin Doorbar
  • David R. FriendEmail author
Original Article

Abstract

The objectives of this work were to evaluate the in vitro release and in vivo pharmacokinetics and local tolerability of a novel, segmented ethylene-vinyl acetate (EVA) intravaginal ring (IVR) delivering progesterone (P) in drug-naïve ovariectomized female Dorset crossbred sheep. Following preparation and assessment of in vitro release of P, animals were randomized into one of six treatment groups: group 1 Crinone® 8% gel (90 mg); group 2 Prometrium® 200-mg capsules; group 3 placebo IVR; group 4 progesterone (P) IVR 4 mg/day; group 5 P IVR 8 mg/day; or group 6 P IVR 12 mg/day. Crinone 8% gel and Prometrium capsules were administered once daily for 28 days. IVRs were inserted vaginally on day 1 and remained in place through day 14; a new ring was administered on day 15 and was removed at day 28. Animals underwent daily examinations to confirm ring placement, and vaginal irritation was scored from 0 (none) to 4 (severe). Blood samples were taken at scheduled times for pharmacokinetic analysis. Postmortem examinations performed on all IVR groups included vaginal irritation, macroscopic, and microscopic evaluations, including irritation scoring and histopathology. Intravaginal rings were retained over 28 days in all animals. Clinical observations showed no significant abnormal findings in any group. Pharmacokinetic analysis in animals showed sustained release of P over from days 0 through 14 of ring use. Irritation scores and microscopic assessments were consistent with the IVRs being well tolerated. These results will guide future human clinical studies to ultimately develop an IVR for use in women for the prevention of preterm birth.

Keywords

Intravaginal Progesterone Pharmacokinetics Preterm birth 

Notes

Acknowledgments

The authors wish to thank QPharma (ring manufacture), MPI Research, a Charles River Company for conducting the animal study, and Pyxant Laboratories for performing the bioanalytical work.

Funding information

The financial support for this study was provided by Juniper Pharmaceuticals.

Supplementary material

13346_2019_646_MOESM1_ESM.docx (16 kb)
ESM 1 (DOCX 15 kb)
13346_2019_646_MOESM2_ESM.docx (17 kb)
ESM 2 (DOCX 16 kb)

References

  1. 1.
    Lawn JE, Gravett MG, Nunes TM, Rubens CE, Stanton C, Group tGR. Global report on preterm birth and stillbirth (1 of 7): definitions, description of the burden and opportunities to improve data. BMC Pregnancy Childbirth. 2010;10(1):S1.  https://doi.org/10.1186/1471-2393-10-s1-s1.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Preterm birth. Centers for Disease Control and Prevention. 2016. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm. Accessed 13 August 2018 2018.
  3. 3.
    Infant Mortality. Centers for disease control and prevention. 2016. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/infantmortality.htm. Accessed 13 August 2018 2018.
  4. 4.
    March of Dimes. Save the children. Born too soon: the global action report on preterm birth. In: Howson C, Kinney M, Lawn J, editors. Geneva: WHO; 2012.Google Scholar
  5. 5.
    Blanks AM, Brosens JJ. Progesterone action in the myometrium and decidua in preterm birth. Facts Views Vis Obgyn. 2012;4(3):33–43.PubMedGoogle Scholar
  6. 6.
    Gellersen B, Fernandes MS, Brosens JJ. Non-genomic progesterone actions in female reproduction. Hum Reprod Update. 2009;15(1):119–38.  https://doi.org/10.1093/humupd/dmn044.CrossRefPubMedGoogle Scholar
  7. 7.
    Caritis SN, Feghali MN, Grobman WA, Rouse DJ. What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth. Semin Perinatol. 2016;40(5):273–80.  https://doi.org/10.1053/j.semperi.2016.03.002.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357(5):462–9.  https://doi.org/10.1056/NEJMoa067815.CrossRefPubMedGoogle Scholar
  9. 9.
    De Franco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30(5):697–705.  https://doi.org/10.1002/uog.5159.CrossRefGoogle Scholar
  10. 10.
    Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth with sonographic short cervix: a multicenter, randomized, double-blind,placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38(1):18–31.  https://doi.org/10.1002/uog.9017.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Winer N, Bretelle F, Senat M-V, Bohec C, Deruelle P, Perrotin F, et al. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2015;212(4):485.e1-.e10.  https://doi.org/10.1016/j.ajog.2014.10.1097.CrossRefPubMedGoogle Scholar
  12. 12.
    Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol. 2012;207(5):390.e1-.e8.  https://doi.org/10.1016/j.ajog.2012.09.013.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kimball AB, Javorsky E, Ron ES, Crowley W, Langer R. A novel approach to administration of peptides in women: systemic absorption of a GnRH agonist via transvaginal ring delivery system. J Control Release. 2016;233:19–28.  https://doi.org/10.1016/j.jconrel.2016.04.035.CrossRefPubMedGoogle Scholar
  14. 14.
    Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82(3):377–90.Google Scholar
  15. 15.
    Eckstein P, Jackson MCN, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spericidal preparations in rabbits and monkeys. J Reprod Fertil. 1969;20(1):85–93.  https://doi.org/10.1530/jrf.0.0200085.CrossRefPubMedGoogle Scholar
  16. 16.
    Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller A-B. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health. 2013;10(1):S2.  https://doi.org/10.1186/1742-4755-10-s1-s2.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sipola-Leppänen M, Vääräsmäki M, Tikanmäki M, Matinolli H-M, Miettola S, Hovi P, et al. Cardiometabolic risk factors in young adults who were born preterm. Am J Epidemiol. 2015;181(11):861–73.  https://doi.org/10.1093/aje/kwu443.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tikanmäki M, Tammelin T, Sipola-Leppänen M, Kaseva N, Matinolli H-M, Miettola S, et al. Physical fitness in young adults born preterm. Pediatrics. 2016;137(1):e20151289.  https://doi.org/10.1542/peds.2015-1289.CrossRefGoogle Scholar
  19. 19.
    Norman M. Preterm birth and the shape of the heart. Circulation. 2013;127(2):160–1.  https://doi.org/10.1161/CIRCULATIONAHA.112.152827.CrossRefPubMedGoogle Scholar
  20. 20.
    Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012;206(2):124.e1-.e19.  https://doi.org/10.1016/j.ajog.2011.12.003.CrossRefPubMedGoogle Scholar
  21. 21.
    Conde-Agudelo A, Romero R, Nicolaides K, Chaiworapongsa T, O'Brien JM, Cetingoz E, et al. Vaginal progesterone vs cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. Am J Obstet Gynecol. 2013;208(1):42.e1-.e18.  https://doi.org/10.1016/j.ajog.2012.10.877.CrossRefPubMedGoogle Scholar
  22. 22.
    Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev 2013(7). doi: https://doi.org/10.1002/14651858.CD004947.pub3.
  23. 23.
    Nguyen BT, Jensen JT. Evaluating the efficacy and safety of a progestin- and estrogen-releasing ethylene vinyl acetate copolymer contraceptive vaginal ring. Expert Opin Drug Saf. 2014;13(10):1423–30.  https://doi.org/10.1517/14740338.2014.948842.CrossRefPubMedGoogle Scholar
  24. 24.
    Roumen FJME, Mishell DR. The contraceptive vaginal ring, NuvaRing®, a decade after its introduction. Eur J Contracept Reprod Health Care. 2012;17(6):415–27.  https://doi.org/10.3109/13625187.2012.713535.CrossRefPubMedGoogle Scholar
  25. 25.
    Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception. 2010;82(5):418–27.  https://doi.org/10.1016/j.contraception.2010.04.012.CrossRefPubMedGoogle Scholar
  26. 26.
    van Laarhoven JAH, Kruft MAB, Vromans H. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int J Pharm. 2002;232(1):163–73.  https://doi.org/10.1016/S0378-5173(01)00900-0.CrossRefPubMedGoogle Scholar
  27. 27.
    Matlin SA, Belenguer A, Hall PE. Progesterone-releasing vaginal rings for use in postpartum contraception. I. In vitro release rates of progesterone from core-loaded rings. Contraception. 1992;45(4):329–41.  https://doi.org/10.1016/0010-7824(92)90055-X.CrossRefPubMedGoogle Scholar
  28. 28.
    Nath A, Sitruk-Ware R. Progesterone vaginal ring for contraceptive use during lactation. Contraception. 2010;82(5):428–34.  https://doi.org/10.1016/j.contraception.2010.05.016.CrossRefPubMedGoogle Scholar
  29. 29.
    RamaRao S, Clark H, Merkatz R, Sussman H, Sitruk-Ware R. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception. 2013;88(5):591–8.  https://doi.org/10.1016/j.contraception.2013.05.004.CrossRefPubMedGoogle Scholar
  30. 30.
    Carr SL, Gaffield ME, Dragoman MV, Phillips S. Safety of the progesterone-releasing vaginal ring (PVR) among lactating women: a systematic review. Contraception. 2016;94(3):253–61.  https://doi.org/10.1016/j.contraception.2015.04.001.CrossRefPubMedGoogle Scholar
  31. 31.
    Dragonis C, Maltaris T, Binder H, Kat M, Mueller A, Cupisti S, et al. Progesterone bioavailability with a progesterone-releasing silicone vaginal ring in IVF candidates. Eur J Med Res. 2007;12:264–7.Google Scholar
  32. 32.
    Stadtmauer L, Silverberg KM, Ginsburg ES, Weiss H, Howard B. Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertil Steril. 2013;99(6):1543–9.  https://doi.org/10.1016/j.fertnstert.2012.12.052.CrossRefPubMedGoogle Scholar
  33. 33.
    Stadtmauer L, Harrison DD, Boyd J, Bocca S, Oehninger S. Pilot study evaluating a progesterone vaginal ring for luteal-phase replacement in donor oocyte recipients. Fertil Steril. 2009;92(5):1600–5.  https://doi.org/10.1016/j.fertnstert.2008.08.085.CrossRefPubMedGoogle Scholar
  34. 34.
    Stadtmauer L, Waud K. Progesterone vaginal ring for luteal support. J Obstet Gynaecol India. 2015;65(1):5–10.  https://doi.org/10.1007/s13224-014-0634-0.CrossRefPubMedGoogle Scholar
  35. 35.
    Zegers-Hochschild F, Balmaceda JP, Fabres C, Alam V, Mackenna A, Fernández E, et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Hum Reprod. 2000;15(10):2093–7.  https://doi.org/10.1093/humrep/15.10.2093.CrossRefPubMedGoogle Scholar
  36. 36.
    Romero R, Nicolaides KH, Conde-Agudelo A, O'Brien JM, Cetingoz E, Da Fonseca E, et al. Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol. 2016;48(3):308–17.  https://doi.org/10.1002/uog.15953.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Norman JE, Bennett P. Preterm birth prevention—time to PROGRESS beyond progesterone. PLoS Med. 2017;14(9):e1002391.  https://doi.org/10.1371/journal.pmed.1002391.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Controlled Release Society 2019

Authors and Affiliations

  1. 1.Todos Medical Ltd.West HempsteadUSA
  2. 2.Department of General Internal MedicineYale University School of MedicineNew HavenUSA
  3. 3.Endorheum ConsultantsMalvernUSA
  4. 4.MPI Research, A Charles River CompanyMattawanUSA
  5. 5.WestchesterUSA
  6. 6.ThatchamUK
  7. 7.Daré Bioscience, Inc.San DiegoUSA

Personalised recommendations